RecruitingISRCTN18014168
Evaluation of NBI-1117570 in adults with stable schizophrenia
Research studyAges 18–55United Kingdom
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- United Kingdom
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Neurocrine Biosciences (United States)
- Sponsor type
- Biotech company
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- ISRCTN18014168
- Official title
Show the full official title
Evaluation of NBI-1117570 in adults with stable schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Neurocrine Biosciences (United States).
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Clozapine versus usual second-line treatment after a first schizophrenia treatment fails
A clinical trial to investigate how effective a stimulant medication is compared to a non-stimulant medication in patients who have been diagnosed with attention deficit hyperactivity disorder (ADHD) and also have a history of either psychosis or Bipolarity